The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study

Journal of Hepatology

Volumn 54, Issue 3, 2011, Pages 489-496

  Cotte, Laurent ^a,b   Bénet, Thomas ^c   Billioud, Claire ^a   Miailhes, Patrick ^a,b   Scoazec, Jean Yves ^a,c   Ferry, Tristan ^a,c   Brochier, Corinne ^a   Boibieux, André ^a   Vanhems, Philippe ^a,c   Chevallier, Michle ^d   Zoulim, Fabien ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d Laboratoire Biomnis   (France)

Author keywords

Didanosine; HIV; Nodular regenerative hyperplasia; Non cirrhotic portal hypertension; Nucleoside; Stavudine; Tenofovir

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MALE; NODULAR HYPERPLASIA; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; HYPERPLASIA; HYPERTENSION, PORTAL; LIVER; LIVER REGENERATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 79951681146     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.07.030     Document Type: Article

References (40)

1. P.E. Steiner Nodular regenerative hyperplasia of the liver Am J Pathol 35 1959 943 953
2. I.R. Wanless Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules Hepatology 11 1990 787 797 (Pubitemid 20191384)
3. L.D. DeLeve Hepatic microvasculature in liver injury Semin Liver Dis 27 2007 390 400
4. T.D. Schiano, D.P. Kotler, E. Ferran, and M.I. Fiel Hepatoportal sclerosis as a cause of non-cirrhotic portal hypertension in patients with HIV Am J Gastroenterol 120 2007 2536 2540 (Pubitemid 47631766)
5. S. Saifee, D. Joelson, J. Braude, R. Shrestha, M. Johnson, and M. Sellers Non-cirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection Clin Gastroenterol Hepatol 6 2008 1167 1169
6. I. Maida, P. Garcia-Gasco, G. Sotgiu, M. José Rios, M.E. Vispo, and L. Martin-Samaniego Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome Antivir Ther 13 2008 103 107 (Pubitemid 351541679)
7. P.E. Chang, R. Miquel, J.L. Blanco, M. Laguno, M. Bruguera, and J.G. Abraldes Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy Am J Gastroenterol 104 2009 1707 1714
8. E. Vispo, A. Moreno, I. Maida, P. Barreiro, A. Cuevas, and S. Albertos Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings AIDS 24 2010 1171 1176
9. P. Podevin, G. Spiridon, B. Terris, L. Chauvelot-Moachon, L. Guillevin, and S. Chaussade Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient AIDS 20 2006 313 315
10. V. Mallet, P. Blanchard, V. Verkarre, A. Vallet-Pichard, H. Fontaine, and C. Lascoux-Combe Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients AIDS 21 2007 187 192 (Pubitemid 46036926)
11. B. Arey, M. Markov, J. Ravi, E. Prevette, K. Batts, and A. Nadir Nodular regenerative hyperplasia of liver as consequence of ART AIDS 21 2007 1066 1068 (Pubitemid 46684349)
12. L.J. Garvey, E.C. Thomson, J. Lloyd, G.S. Cooke, R.D. Goldin, and J. Main Response to Mallet et al. 'Nodular regenerative hyperplasia as a new cause of chronic liver disease in HIV-infected patients' AIDS 21 2007 1494 1495 (Pubitemid 46988016)
13. P.F. Sandrine, A. Sylvie, E. Andre, D. Abdoulaye, L. Bernard, and C. Andre Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 21 2007 1498 1499 (Pubitemid 46988019)
14. M. Tateo, M. Sebagh, M.P. Bralet, Elina Teicher, D. Azoulay, and V. Mallet A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients Liver Transpl 14 2008 1194 1198
15. I. Maida, M. Nunez, M.J. Rios, L. Martin-Carbonero, G. Sotgiu, and C. Toro Severe liver disease associated with prolonged exposure to antiretroviral drugs J Acquir Immune Deficit Syndr 42 2006 177 182 (Pubitemid 43884712)
16. H. Kovari, B. Ledergerber, U. Peter, M. Flepp, J. Jost, and P. Schmid Association of non-cirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study Clin Infect Dis 49 2009 626 635
17. V. Mallet, A. Varthaman, D. Lasne, J.P. Viard, H. Goya, and D. Brogel Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients AIDS 23 2009 1 8
18. A.N. Phillips, S. Grabar, J.M. Tassie, D. Costagliola, J.D. Lundgren, and M. Egger Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups AIDS 13 1999 2075 2082 (Pubitemid 29509584)
19. I.R. Wanless Terminology of nodular hepatocellular lesions. International Working Party Hepatology 22 1995 983 993
20. T. Roskams, A. Baptista, L. Bianchi, A. Burt, F. Callea, and H. Denk Histology of portal hypertension: a practical guideline Histopathology 42 2003 2 13 (Pubitemid 36062561)
21. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, Brezault, and M. Le Charpentier Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 2004 460 466 (Pubitemid 38444550)
22. A. Mocroft, J. Gatell, P. Reiss, B. Ledergerber, O. Kirk, and S. Vella Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study AIDS 16 2002 1663 1671 (Pubitemid 34921112)
23. C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet, and D. Costagliola Changes in causes of death among adults infected by HIV between 2000 and 2005: The ''Mortalité 2000 and 2005" Surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr 48 2008 590 598
24. A. Carr, A. Morey, P. Mallon, D. Williams, and D.R. Thorburn Fatal hypertension, liver failure and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia Lancet 357 2001 1412 1414 (Pubitemid 32455372)
25. M. Nunez Hepatotoxicity of antiretrovirals: incidence, mechanisms and management J Hepatol 44 2006 S132 S139
26. A.H.J. Naber, U. Van Haelst, and S.H. Yap Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients J Hepatol 12 1991 94 99
27. R. Fleischer, D. Boxwell, and K.E. Sherman Nucleoside analogues and mitochondrial toxicity Clin Infect Dis 38 2004 e79 e80
28. A.S. Ray, L. Olson, and A. Fridland Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir or Tenofovir Antimicrob Agents Chemother 48 2004 1089 1095 (Pubitemid 38405459)
29. P. Barreiro, and V. Soriano Suboptimal CD4 gains in HIV-infected patients receiving didanosine and Tenofovir J Antimicrob Chemother 57 2006 806 809
30. B.P. Kearney, J.R. Sayre, J.F. Flaherty, S.S. Chen, S. Kaul, and A.K. Cheng Drug-drug and drug-food interactions between Tenofovir disoproxil fumarate and didanosine J Clin Pharmacol 45 2005 1360 1367 (Pubitemid 41642438)
31. M. Jones, P. Best, and G. Catto Is nodular regenerative hyperplasia of the liver associated with azathioprine therapy after renal transplantation? Nephrol Dial Transplant 3 1988 331 333
32. N.Y. Habouri, H.H. Ali, H.L. Whitwell, and P. Ackrill Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations Am J Gastroenterol 83 1988 256 261
33. E. Gane, B. Portmann, R. Saxena, P. Wong, J. Ramage, and R. Williams Nodular regenerative hyperplasia of the liver graft after liver transplantation Hepatology 20 1994 88 94 (Pubitemid 24196495)
34. F. Daniel, J.F. Cadranael, P. Seksik, A. Cazier, J.P. Duong Van Huyen, and M. Ziol Azathioprine induced nodular regenerative hyperplasia in IBD patients Gastroenterol Clin Biol 29 2005 660 663
35. D.P. Breen, A.M. Marinaki, M. Arenas, and P.C. Hayes Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation Liver Transpl 11 2005 826 833 (Pubitemid 40975585)
36. B.P. Kearney, A. Mathias, A. Mittan, J. Sayre, R. Ebrahimi, and A.K. Cheng Pharmacokinetics and safety of Tenofovir disoproxil fumarate on coadministration with lopinavir/Ritonavir J Acquir Immune Defic Syndr 43 2006 278 283 (Pubitemid 44674007)
37. J.J. Kiser, M.L. Carten, C.L. Aquilante, P.L. Anderson, P. Wolfe, and T.M. King The effect of Lopinavir/Ritonavir on the renal clearance of Tenofovir in HIV-infected patients Clin Pharmacol Ther 83 2008 265 272
38. N. Venhoff, B. Setzer, K. Melkaoui, and U.A. Walker Mitochondrial toxicity of Tenofovir, Emtricitabine and Abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors Antivir Ther 12 2007 1075 1085 (Pubitemid 350114988)
39. D. Lebrecht, A.C. Venhoff, J. Kirschner, T. Wiech, N. Venhoff, and U.A. Walker Mitochondrial tubulopathy in Tenofovir disoproxil fumarate-treated rats J Acquir Immune Defic Syndr 51 2009 258 263
40. US Department of Health and Human Services, Food and Drug Administration [Internet]. Silver Spring (MD): US Food and Drug Administration; [cited 2010 january 29]: FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine). Available from: .